Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $253

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $234 to $253.